Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

• Published in: Frontiers in immunology Vol. 15; p. 1308109
• Main Authors: Lorenzi, Martina, Resi, Maria Vittoria, Bonanno, Laura, Frega, Stefano, Dal Maso, Alessandro, Ferro, Alessandra, Guarneri, Valentina, Pasello, Giulia
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2024
• Subjects: biomarkers; ES-SCLC; extensive stage small-cell lung cancer; immune checkpoint inhibitors (ICIs); Immunology; liquid biopsy; predictive role; extensive stage small-cell lung cancer; tumor immune microenvironment; biomarkers; ES-SCLC; immune checkpoint inhibitors (ICIs); predictive role; liquid biopsy

Extensive stage-Small-Cell Lung Cancer (ES-SCLC) is an aggressive cancer with dismal prognosis. The addition of immune-checkpoint inhibitors (ICIs) to platinum-based chemotherapy have been consistently demonstrated to improve outcomes and survival, becoming the new standard in first - line treatment...